ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1946

Development of a Multi-Component 3D Arthritic Joint Model

Alexandra Damerau1,2, Lisa Ehlers1,2, Moritz Pfeiffenberger1,2, Igor Ponomarev3, Frank Buttgereit2,4, Timo Gaber4,5 and Annemarie Lang1,2, 1Rheumatologie und klinische Immunologie, Charité-Universitätsmedizin Berlin, Berlin, Germany, 2Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 3Research Center of Medical Technology and Biotechnology, Bad Langensalza, Germany, 4Rheumatologie und klinische Immunologie, Charité Universitätsmedizin Berlin, Berlin, Germany, 5German Rheumatism Research Center (DRFZ) Berlin, Berlin, Germany

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Bone, cartilage and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Biology and Pathology of Bone and Joint Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Our goal is to develop an in vitro 3D joint model to simulate the immune mediated pathogenesis of arthritides in order to present an alternative experimental setup for traditional animal models. There are currently no appropriate in vitro models capable of simulating an arthritic joint in such a comprehensive way that all relevant humoral and cellular factors as well as the different tissue types are involved. Therefore, we work to establish an in vitro 3D healthy joint model, followed by the simulation of an arthritic joint. The in vitro 3D joint model is planned to consist of an (1) osteogenic part and (2) a chondrogenic part, (3) the joint space with synovial fluid, and (4) the synovial membrane.

Development of the first two components of our in vitro 3D joint model, namely (1) the osteogenic and (2) the chondrogenic part.

Methods:

We used β-tricalcium phosphate (TCP) with 60% porosity as the mineral part of our osteogenic model. This substrate was populated with human bone marrow derived mesenchymal stromal cells (hMSC) predifferentiated towards the osteoblastic lineage and then cultured for up to 21 days under normoxic conditions (37 °C, 18% O2). The adhesion of the cells and their structural integrity were evaluated by Scanning Electron Microscopy and Laser Scanning Microscopy. To confirm cell attachment and biocompatibility of β-TCP particles, cellular release of LDH (after 1 d) was assessed, and LIVE/DEAD staining was applied (1, 7, 14, 21 d). Osteogenic differentiation was verified on gene expression level using qRT-PCR. The chondrogenic model, a scaffold-free 3D cartilage construct (fzmb GmbH), was generated using native hMSC. Chondrogenic differentiation was performed under hypoxia (37 °C, 1% O2) with intermittent mechanical stimulation and analyzed by histology (HE staining) and immunohistology (Col1a1, Col2a1, Alcian Blue).

Results:

We have been able to successfully develop an in vitro 3D bone model by seeding predifferentiated hMSC (after 24-hour preincubation with osteogenic medium) on a β-TCP scaffold. The analysis of cell viability via LDH detection did not show any toxic effects during cultivation of the cells seeded. Histological and immunofluorescence analyses demonstrated good cell attachment, cell integrity and metabolic activity of the β-TCP scaffold until day 21, demonstrating the good suitability of both the scaffold and the cultivation method. mRNA expression of bone-related genes such as RUNX2, SPP1 and COL1A1 confirmed phenotypic changes as induced during osteogenic differentiation. The development of a cartilage phenotype from the accordingly differentiated hMSC was confirmed by HE and Alcian Blue staining as well as by Col1a1 and Col2a1 expression. Histological analyses performed after 21 d of co-cultivation showed successful colonization, connectivity and initial calcification implying a functional transitional bridging area.

Conclusion: These initial results from our in vitro 3D models confirm good cell vitality indicating successful progression of developing our model. This 3D multi-component joint model should enable us to simulate arthritis and to study the efficacy of drug treatment in vitro.


Disclosure: A. Damerau, None; L. Ehlers, None; M. Pfeiffenberger, None; I. Ponomarev, None; F. Buttgereit, None; T. Gaber, None; A. Lang, None.

To cite this abstract in AMA style:

Damerau A, Ehlers L, Pfeiffenberger M, Ponomarev I, Buttgereit F, Gaber T, Lang A. Development of a Multi-Component 3D Arthritic Joint Model [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/development-of-a-multi-component-3d-arthritic-joint-model/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-a-multi-component-3d-arthritic-joint-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology